Delving into the Latest Updates on Insulin glargine (Sanofi) with Synapse

Overview

Basic Info

Drug Type

Hormone

Synonyms

Insulin Glargine (Genetical Recombination), INSULIN GLARGINE RECOMBINANT, GLA-100

+ [14]

Target

INSR

Action

agonists

Mechanism

INSR agonists(Insulin receptor agonists)

Therapeutic Areas

Immune System DiseasesEndocrinology and Metabolic Disease

Active Indication

Diabetes MellitusDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2

Inactive Indication

Acute myocardial infarctionDiabetes Mellitus, Noninsulin-Dependent, 2Diabetic Coma+ [5]

Originator Organization

Sanofi

Active Organization

Sanofi

Sanofi-Aventis U.S. LLCSanofi-Aventis Australia Pty Ltd.

+ [2]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

United States (20 Apr 2000),

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 4851

Source: *****

Sequence Code 31960

Source: *****

This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment participants get is decided by chance. Insulin icodec is the new medicine being tested, while insulin glargine is already approved and can be prescribed by doctors. Participants will get one injection of insulin icodec once a week, or one injection of insulin glargine once a day, depending on the treatment group participants are assigned into. Participants will use a pen with a small needle to inject the medicine under participants skin into participants thigh, upper arm or stomach.The study will last for about 9 months, but participants will only be taking the study medicine for 6 months.

Start Date19 Apr 2024

Sponsor / Collaborator

Novo Nordisk A/S

100 Clinical Results associated with Insulin glargine (Sanofi)

Login to view more data

100 Translational Medicine associated with Insulin glargine (Sanofi)

Login to view more data

100 Patents (Medical) associated with Insulin glargine (Sanofi)

Login to view more data

3,330

Literatures (Medical) associated with Insulin glargine (Sanofi)

01 May 2025·DIABETES OBESITY & METABOLISM

Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin‐naive adults with suboptimally controlled type 2 diabetes

Article

Author: Dex, Terry ; Meneghini, Luigi ; Polonsky, William H. ; Rodrigues, Amélie ; Shah, Viral N.

Abstract:

Aims:

In Soli‐CGM, treatment with iGlarLixi (insulin glargine 100 U/mL and lixisenatide 33 μg/mL) in insulin‐naive adults with suboptimally controlled type 2 diabetes (T2D; haemoglobin A1c 9%–13% on ≥2 oral antihyperglycaemic agents (OADs) ± glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy) increased time in range (TIR; primary endpoint) from 26.4% at baseline to 52.7% at Week 16. This exploratory analysis examined the impact of treatment with iGlarLixi on patient‐reported treatment satisfaction.

Materials and Methods:

Soli‐CGM was a single‐arm, 16‐week, multicentre, interventional, open‐label, phase 4 study using blinded continuous glucose monitoring (CGM; FreeStyle Libre Pro) to assess glycaemic metrics (N = 124). CGM data were collected for a 2‐week period before initiation of iGlarLixi, and after treatment with iGlarLixi (Weeks 14–16). Treatment satisfaction was assessed using the Diabetes Medication Treatment Satisfaction Tool (DM‐SAT, which comprises four domains: well‐being, medical control, lifestyle and convenience), at baseline and end‐of‐treatment. Association of TIR and overall satisfaction (sum of all items) was also assessed.

Results:

Overall, 118 (95.9%) and 107 (87.0%) participants completed the DM‐SAT at baseline and Week 16, respectively. Mean overall score increased by 0.18, from 0.59 (baseline) to 0.78 (Week 16). A trend in improvement in score was observed in all domains. Improvement in TIR had a positive, but weak, trend of association with improvement in overall treatment satisfaction (mean r = 0.14).

Conclusions:

In people with T2D suboptimally controlled on ≥2 OADs ± GLP‐1 RA, 16 weeks' treatment with iGlarLixi resulted in a trend of improvement in treatment satisfaction.

01 May 2025·Value in Health Regional Issues

Cost-Effectiveness Analysis of Pharmacological Treatment With Insulin and Insulin Analogs for Type 1 and Type 2 Diabetes Mellitus in Colombia

Article

Author: Arango, Luz Karime Osorio ; Ibáñez, Diego Fernando Ávila ; Ramirez, Luis Esteban Orozco ; Plazas, Merideidy ; Escobar, Ivan Darío ; Morales, Christian Camilo Anzola

OBJECTIVES:

This study aimed to estimate the cost-effectiveness relationship of insulins and insulin analogs in diabetes mellitus type 1 (DM1) and 2 (DM2), from the perspective of the Colombian health system.

METHODS:

A short-term decision tree model (SM) was built, the outcome of which was severe/nocturnal hypoglycemia, and a long-term Markov model for quality-adjusted life-years. The probabilities were calculated through a literature review of effectiveness and safety. The costs are estimated from official databases. Deterministic and probabilistic sensitivity analyses were performed.

RESULTS:

For DM1, in prandial insulins, and for both models, the cost-effective interventions (CEIs) are aspartate and lispro. In basal insulins, the CEIs are NPH and glargine U-100 in both models. In the comparison of detemir and NPH, detemir generates lower nocturnal hypoglycemia and higher quality-adjusted life-years; however, in the long-term Markov model, the incremental cost-effectiveness ratio exceeds the threshold. For DM2, in the prandial insulin, and for both models, aspartate is a CEI and the glargine U-300 is also a CEI in the SM. In basal insulin, the CEIs are glargine U-100 and detemir (for nocturnal hypoglycemia) in both models and glargine U-300 is also a CEI in the SM. Finally, in the group of combinations, iGlarLixi is dominant over IDegLira.

CONCLUSIONS:

The results favor the use of analog insulins over human insulins, the former reducing the possibility of acute events and chronic complications to a greater extent.

01 May 2025·DIABETES OBESITY & METABOLISM

iGlarLixi provides improved early glycaemic control after 12 weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN studies

Article

Author: Du, Qin ; Huang, Shan ; Zhang, Yawei ; Lauand, Felipe ; Yuan, Xiaoyong ; Song, Lulu ; Zhang, Jie ; Guo, Xiaohui ; Yang, Wenying ; Kang, Lei ; Wang, Zhini

Abstract:

Aims:

To evaluate early glycaemic control (glycated haemoglobin [HbA1c] < 7.0% [<53.0 mmol/mol], fasting plasma glucose [FPG] ≤ 7.0 mmol/L or postprandial glucose [PPG] ≤ 10.0 mmol/L) with iGlarLixi versus insulin glargine 100 U/mL (Gla‐100) in Asian people with suboptimally controlled type 2 diabetes (T2D) on oral antidiabetic drugs (OADs) in LixiLan‐O‐AP or basal insulin (BI) ± OADs in LixiLan‐L‐CN.

Materials and Methods:

This post hoc analysis evaluated changes from baseline to Week 12 in HbA1c, FPG and PPG, hypoglycaemia incidence and the rates of target HbA1c achievement at Weeks 8 and 12. Median time to glycaemic control (i.e., time to 50% achieving target HbA1c, FPG or PPG) was also assessed.

Results:

At Week 12, mean HbA1c reductions were greater with iGlarLixi versus Gla‐100 in LixiLan‐O‐AP (−1.6% vs. −1.1% [−17.0 vs. −12.0 mmol/mol]) and LixiLan‐L‐CN (−1.3% vs. −0.5% [−13.9 vs. −5.4 mmol/mol]). PPG reductions were greater with iGlarLixi, while FPG reductions and hypoglycaemia incidence were similar. At Weeks 8 and 12, more participants had achieved target HbA1c or PPG with iGlarLixi versus Gla‐100 in both studies. Median time to achieve HbA1c and PPG targets was shorter with iGlarLixi versus Gla‐100 in LixiLan‐O‐AP (85 vs. 126 days and 84 vs. 167 days) and LixiLan‐L‐CN (85 vs. 239 days and 85 days vs. not estimable); median time to achieve FPG target was similar in LixiLan‐O‐AP (57 vs. 57 days) and LixiLan‐L‐CN (29 vs. 30 days).

Conclusions:

In Asian people with T2D suboptimally controlled on OADs or BI, iGlarLixi provided comprehensive earlier glycaemic control than Gla‐100.

148

News (Medical) associated with Insulin glargine (Sanofi)

10 Apr 2025

·pipelinereview.com

Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio

BRIDGEWATER, NJ, USA and BENGALURU, Karnataka, India I April 10, 2025 I Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevne™ (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use. JOBEVNE, a recombinant humanized monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin® (bevacizumab). JOBEVNE is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis – combating cancer by restricting blood supply to the tumor. The approval of JOBEVNE expands Biocon Biologics’ biosimilar oncology portfolio in the United States, which also includes OGIVRI (Trastuzumab-dkst) and FULPHILA (Pegfilgrastim-jmdb). The Company also markets Bevacizumab in Europe (approved February 2021) and Canada (approved November 2021) under the name ABEVMY. Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd. , said: “The U.S. FDA approval of JOBEVNE™ (bevacizumab-nwgd) is a significant milestone—our seventh biosimilar approved in the U.S. and a strong addition to our robust oncology portfolio. It underscores the depth of our scientific expertise and commitment to expanding access to high-quality, affordable biologics. We look forward to working with all stakeholders to bring more treatment options to patients.” In the U.S., sales of bevacizumab were approximately $2.0 billion in 2023.** Biocon Biologics is a leading global player in biosimilars and insulin production and has achieved many “firsts” in the industry including the first to receive approval of a trastuzumab in the United States, OGIVRI (Trastuzumab-dkst), as well as FULPHILA (Pegfilgrastim-jmdb) and the first U.S. approval of an interchangeable biosimilar for SEMGLEE (insulin glargine). Serving over 5 million patients annually, Biocon Biologics has a comprehensive portfolio of in-market and in-development biosimilar products across multiple therapies, including seven approved biosimilars in the United States and six in Canada, with a robust development pipeline of 20 biosimilar assets, including insulins and monoclonal antibodies spanning multiple therapy areas. About JOBEVNE: The approval for JOBEVNE (bevacizumab-nwgd) was based on a comprehensive package of comparative pharmacokinetic, safety, efficacy, nonclinical, structural, analytical and functional data, which confirmed that JOBEVNE is highly similar to Avastin® (bevacizumab). The data demonstrated that there were no clinically meaningful differences between JOBEVNE and Avastin® in terms of pharmacokinetics, safety, efficacy, and immunogenicity. INDICATIONS AND USAGE: JOBEVNE is a vascular endothelial growth factor inhibitor indicated for the treatment of: * Limitations of Use: JOBEVNE is not indicated for adjuvant treatment of colon cancer. JOBEVNE is a trademark of Biosimilars Newco Limited, a Biocon Biologics Company. OGIVRI, FULPHILA, SEMGLEE and ABEVMY are registered trademarks of Biosimilars Newco Limited, a Biocon Biologics Company. BIOCON BIOLOGICS and the Biocon Biologics Logo are registered trademarks of Biocon Biologics Limited. All other trademarks are the property of their respective owners. **Sales projections are based on Biocon Biologics’ analysis of IQVIA 2023 data. About Biocon Biologics Limited: Biocon Biologics Ltd. (BBL) , a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its ‘lab to market’ capabilities to serve millions of patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. Biocon Biologics has commercialized nine biosimilars from its pipeline of 20 products in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It’s pipeline has several biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website www.bioconbiologics.com ; Follow us on X (formerly Twitter ): @BioconBiologics and LinkedIn : Biocon Biologics for company updates. Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com ; Follow-us on X (formerly Twitter ) @bioconlimited and LinkedIn : Biocon for company updates. SOURCE: Biocon Biologics

Drug ApprovalImmunotherapy

21 Feb 2025

·endpts.com

Teva launches Stelara biosimilar at 85% discount as wider field emerges

Teva and its partner Alvotech on Friday followed Amgen in launching a biosimilar to Johnson & Johnson’s blockbuster immunosuppressive biologic Stelara, offering a steep discount. The Stelara biosimilar field is shaping up to be a crowded space, even though the government included Stelara in its first round of price negotiations and uptake for other biosimilars in crowded markets has slowed, like with AbbVie’s megablockbuster Humira, where there has been little brand name erosion . As with biosimilars to Humira, the biosimilars to Stelara are already offering a wide range of list prices, with Amgen’s launch at two prices — 5% off the brand name and another at about 80% off, according to Andrew Bourgoin, founder at All Things Biosimilar . Amgen is selling its biosimilars through Optum’s Nuvaila unit, and it isn’t the first to offer two different discounts to a brand-name biologic. The precedent was first set with Viatris’ interchangeable biosimilar for Sanofi’s insulin Lantus, known as Semglee, and continued with Humira, as PBMs often favor high list prices and high rebate products. Teva launched its Stelara biosimilar on Friday at an 85% discount, a spokesperson confirmed to Endpoints News . Two other Stelara biosimilars are also expected to launch by Monday, including Celltrion’s Steqeyma and Biocon’s Yesintek at between 86% and 90% off, Bourgoin said. Fresenius Kabi and Formycon also won approval for their Stelara biosimilar last September , while Accord Biopharma won approval for one last October. In 2024, J&J pulled in a little more than $10 billion from Stelara. While J&J had to go through the first round of drug price negotiations, and the back-and-forth with the government ultimately set a 66% discount off the list price, the biologic may ultimately be de-selected from the Inflation Reduction Act program, depending on how CMS interprets what’s known as “bona fide marketing” in the law. Anna Kaltenboeck, head of prescription drug reimbursement practice at consulting firm ATI Advisory, previously told Endpoints that the determination could depend on “whether or not the biosimilar is taking up market share.”

Drug ApprovalBiosimilar

18 Feb 2025

·www.fiercepharma.com

FDA signs off on Sanofi's insulin biosimilar, the first for Novo Nordisk's rapid-acting NovoLog

Patients that use rapid-acting insulin to help control their blood sugar spikes have a biosimilar option in Sanofi's Merilog, which has gained FDA approval. More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time.The agency has given a thumbs up to Sanofi’s Merilog (insulin-aspart-szjj) as the first biosimilar to Novo Nordisk’s NovoLog for patients with diabetes. Insulin aspart is delivered by a subcutaneous shot 5 to 10 minutes before mealtime to help patients control glucose and limit blood sugar spikes.Merilog will be provided by prefilled pen in a 3 mL dose or in a multiple-dose 10 mL vial. It is for adults and pediatric patients age 6 and older.The approval is backed by a phase 3 trial of 597 patients with type 1 and type 2 diabetes who received multiple shots daily. At week 26, blood sugar levels were similar for those who received the biosimilar and those on the reference product, confirming Merilog’s non-inferiority.Of the roughly 38 million in the U.S. with diabetes, 8.4 million use either a rapid-acting or long-acting insulin, or both, the FDA said. The high cost of insulin has led some patients to ration their use, triggering high-profile calls from U.S. lawmakers for companies to drop their prices.In 2023, Eli Lilly revealed a plan to cut the cost of most of its insulins by 70%. Less than two weeks later, Novo Nordisk announced a planned 75% reduction in the cost of NovoLog.Then a few days later, Sanofi followed suit with a 78% slashing of the price of Lantus. The company also said it would cap the monthly out-of-pocket cost for Lantus at $35 for those with commercial insurance. NovoLog and Novo Nordisk’s other rapid-acting insulin follow-on Fiasp are among the drugs subject to government price negotiations under the Inflation Reduction Act. The new prices will be enacted at the start of next year.In July 2021, the FDA approved Biocon and Viatris’ Semglee (insulin glargine-yfgn) as the first biosimilar to Lantus. Five months later, the U.S. regulator endorsed Eli Lilly’s version of the drug, called Rezvoglar (insulin glargine-aglr).

Drug ApprovalPhase 3Clinical Result

100 Deals associated with Insulin glargine (Sanofi)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03250	Insulin glargine (Sanofi)	A10AE04	DB00047

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	European Union	Sanofi-Aventis Deutschland GmbH	09 Jun 2000
Diabetes Mellitus	Iceland	Sanofi-Aventis Deutschland GmbH	09 Jun 2000
Diabetes Mellitus	Liechtenstein	Sanofi-Aventis Deutschland GmbH	09 Jun 2000
Diabetes Mellitus	Norway	Sanofi-Aventis Deutschland GmbH	09 Jun 2000
Diabetes Mellitus, Type 1	United States	Sanofi-Aventis U.S. LLC	20 Apr 2000
Diabetes Mellitus, Type 2	United States	Sanofi-Aventis U.S. LLC	20 Apr 2000

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute myocardial infarction	Phase 3	United States	Sanofi	01 Apr 2008
Acute myocardial infarction	Phase 3	Argentina	Sanofi	01 Apr 2008
Acute myocardial infarction	Phase 3	Brazil	Sanofi	01 Apr 2008
Acute myocardial infarction	Phase 3	Canada	Sanofi	01 Apr 2008
Acute myocardial infarction	Phase 3	Mexico	Sanofi	01 Apr 2008
Diabetic Coma	Phase 3	United States	Sanofi	01 Apr 2008
Diabetic Coma	Phase 3	Argentina	Sanofi	01 Apr 2008
Diabetic Coma	Phase 3	Brazil	Sanofi	01 Apr 2008
Diabetic Coma	Phase 3	Canada	Sanofi	01 Apr 2008
Diabetic Coma	Phase 3	Mexico	Sanofi	01 Apr 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NEWS Manual	Not Applicable	Diabetes Mellitus, Type 2	568	甘精胰岛素U300 (初治)	bifixuxwrj(mvuwoqilxy) = nxyskjoxwq ilbyevhoaq (grsdtxxcbf ) View more	Positive	19 Nov 2024
				甘精胰岛素U300 (基础胰岛素转换)	bifixuxwrj(mvuwoqilxy) = ktotnedppp ilbyevhoaq (grsdtxxcbf ) View more
NCT03406000 (TOP1, Pubmed)	Phase 4	Diabetes Mellitus, Type 1	-	Twice-daily basal insulin	crcyeecazz(uefllbqbmc) = tmabisllxa phjvaqsqzk (mldpjdaiqq ) View more	Positive	09 Jul 2024
ISN WCN2024	Not Applicable	Diabetes Mellitus, Type 2 \| Kidney Failure, Chronic	11	NPH insulin	kkpwyadeen(kksjvoundd) = fngkhmuixi ppwtiinkhd (ewblokkmcw, ±76.9)	Positive	01 Apr 2024
				Glargine insulin	kkpwyadeen(kksjvoundd) = zbylehatlb ppwtiinkhd (ewblokkmcw, ±60.6)
NCT03703869 (Pubmed \| Diabetes Ther)	Not Applicable	Diabetes Mellitus, Type 2	412	Insulin Glargine U300 (Gla-300)	cjofnmfacr(bixcwanpwb) = PROs improved jrueysoojk (apklxzcvme ) View more	Positive	01 Mar 2024
NCT01524705 (FLAT-SUGAR, CTgov)	Phase 4	Diabetes Mellitus, Type 2	102	Insulin Glargine+Metformin+Exenatide	mgxguhhppd(zzmaemvcfu) = csprxpooik znelskijld (yfaqmjksux, 7.89) View more	-	29 Dec 2023
EASD2023	Not Applicable	Diabetes Mellitus, Type 2	-	Insulin glargine 300 U/mL (Gla-300)	idflcojmws(wsfelgmazk) = wunnenftmp jjmwochdlq (nwonoyjepf )	-	05 Oct 2023
				Long-acting basal insulins (BIs)/NPH insulin	idflcojmws(wsfelgmazk) = fexuhtvuzv jjmwochdlq (nwonoyjepf )
NCT00069784 (ORIGIN, ESC2023)	Phase 3	Sex hormone-binding globulin (SHBG) \| testosterone	-	Glargine	kpgbxaphuh(lxtwfeiyuc) = wpepibqnfq girnwmcjzw (hvnqsvlfxn )	-	26 Aug 2023
				Glargine	kpgbxaphuh(lxtwfeiyuc) = szwfbnufbh girnwmcjzw (hvnqsvlfxn )
NCT03874715 (GEMELLI X, CTgov)	Phase 3	Diabetes Mellitus, Type 1	210	Insulin glargine U100+Insulin Aspart SAR341402 (Switching: NovoLog/SAR341402)	cdqjboqsyq(gfxclfpbyf) = mvbpcnkacv vsgczztzjx (dpwymbvwik, 18300) View more	-	21 Jul 2023
				Insulin glargine U100+Insulin Aspart (Non-switching: NovoLog)	cdqjboqsyq(gfxclfpbyf) = dvgigmzcqn vsgczztzjx (dpwymbvwik, 6530) View more
RESTORE-G (ADA2023)	Not Applicable	-	-	Glargine 300 U/mL	svrnfxxmlt(odbnqyytdc) = okvndijtyd kvffgvcxls (tcwbicbwzw )	-	23 Jun 2023
ADA2023	Not Applicable	-	-	Bridging dose of G with first dose of D	wgplgvjtwo(ymjagzdnsv) = bfftmjoqeh jldhpkapmk (pprpcwjtmi )	-	20 Jun 2023
				Placebo	tqypmwzyyi(nsfuepzlvp) = orwuttkhil nnvstoqqnv (jfkvjayhzj )

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data